Genmab

Contact

Thilo Riedl
t.Riedl@genmab.com

 Paul Parren Erik Ensing 

E.Ensing@genmab.com

Added value Genmab for hDMT:

• Extensive Drug development and valuation expertise
• Provide user requirement for device and cell model design from target intervention screening
purpose perspective
• In depth knowledge and expertise in oncogenic drivers, solid tumor and hematology
therapeutic areas and immunology/ immune effector mechanisms
• Complementary expertise in the field of therapeutic antibodies/ biologics
• Proprietary antibody platforms
• Clinically validated antibody based drug compounds and compound libraries
• Expertise in experimental system validation
• Head-to-head model validation (2D/3D cell based assays and (mouse) xenograft in vivo
models)
• High throughput capacities (for testing and validation)
• Alliances and networks with relevant Academia, Biotech, and Pharma
• Experience establishing industry-academia collaborations and alliances

 

Added value hDMT for Genmab:

• Access to cellular test systems with a potential predictive power for drug discovery
• Potential to further reduce animal testing in drug development
• Novel avenues for performing mechanism of action studies
• Access to patient derived cells and associated model systems
• Expand existing networks and open innovation program
• Extended knowledge (biology and technology)
 

Expertise/facilities:

Expertise

• Full spectrum pre-clinical and clinical development expertise for antibody based drugs
• Proven track record to bring antibody based drug to the market (Arzerra)
• Antibody biology
• Oncology and hematology as therapeutic areas
• Immunology and immune effector mechanisms (ADCC, CDC, T-cell activation etc.)
• Identification of new disease targets for antibody-based therapeutics
• Translational knowledge related to cancer pathophysiology
• Drug discovery
• Antibody screening knowledge & capabilities
• Novel antibody formats with enhanced effector functions and biological characteristics
• Broad assay technology base (functional and biophysical)

Facilities/capabilities

• 4000m2 lab and office facility in Utrecht
• State-of-the-art laboratories for Cell and Molecular Biology, Protein Biochemistry
• Cell line development and cell banking
• Protein production and purification
• Immunohistochemistry capabilities (High Throughput)
• High throughput screening facility with automated liquid handling (robots), analysis, and data
handling. Microplate and FACS based
• Various high-end readers and imaging instruments
• Mass spectrometry and other analytical platforms
• Access to cancer and immune system specific in vivo models (mouse)
 

Ongoing projects:

Clinical programs including Daratumumab (HuMax®-CD38) by Janssen Biotech,
Ofatumumab (Arzerra®) by GlaxoSmithKline, and HuMax®-TF-ADC.
An array of pre-clinical programs including HuMax®-AXL-ADC.
Collaborations on DuoBody and HexaBody technology with companies including Janssen
Biotech, Novartis, Eli Lilly, Kirin Kyowa Hakko, and a number of academic institutions including the
Leiden University Medical Center, University Utrecht, University of Virginia Medical School, The
Scripps Research Institute, University of Southern Denmark, University of Patras, University of Kiel.
Technology innovation projects including antibody discovery platforms, cell based assay
technologies (incl. 3D models) amongst others.
Open innovation projects: Genmab is actively stimulating pre-competitive use of its format
technologies to advance science and catalyze the translation from scientific concept to a
product development opportunity.
 

Publications:

• Labrijn, A.F., Meesters, J.I., Priem, P., de Jong, R.N., van den Bremer, E.T., van Kampen, M.D.,
Gerritsen, A.F., Schuurman, J., Parren, P.W. Controlled Fab-arm exchange for the generation
of stable bispecific IgG1. Nat Protoc. 2014;9:2450-63.
• Schuurman, J., Graus, Y.F., Labrijn, A.F., Ruuls, S., Parren, P.W. Opening the door to innovation.
MAbs. 2014;6:812-9.
• Diebolder, C.A., Beurskens, F.J., de Jong, R.N., Koning, R.I., Strumane, K., Lindorfer, M.A.,
Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A.J., van de Winkel, J.G., Wilson, I.A., Koster, A.J.,
Taylor, R.P., Saphire, E.O., Burton, D.R., Schuurman, J., Gros, P., Parren, P.W.. Complement is
activated by IgG hexamers assembled at the cell surface. Science. 2014;343:1260-3.
• de Goeij, B.E., Peipp, M., de Haij, S., van den Brink, E.N., Kellner, C., Riedl, T., de Jong, R.,
Vink, T., Strumane, K., Bleeker, W.K., Parren, P.W. HER2 monoclonal antibodies that do not
interfere with receptor heterodimerization-mediated signaling induce effective internalization
and represent valuable components for rational antibody-drug conjugate design. MAbs.
2014;6:392-402.
• Brei,j E.C., de Goeij, B.E., Verploegen, S., Schuurhuis, D.H., Amirkhosravi, A., Francis, J., Miller,
V.B., Houtkamp, M., Bleeker, W.K., Satijn, D., Parren, P.W. An antibody-drug conjugate that
targets tissue factor exhibits potent therapeutic activity against broad range of solid tumors.
Cancer Res. 2014;74:1214-26.
• Labrijn, A.F., Meesters, J.I., de Goeij, B.E., van den Bremer, E.T,, Neijssen, J., van Kampen,
M.D., Strumane, K., Verploegen S, Kundu A, Gramer MJ, van Berkel PH, van de Winkel JG,
Schuurman J, Parren, P.W. Efficient generation of stable bispecific IgG1 by controlled Fab-arm
exchange. Proc Natl Acad Sci U S A. 2013;110:5145-50.
• Overdijk, M.B., Verploegen, S., van den Brakel, J.H., Lammerts van Bueren, J.J., Vink, T.,
van de Winkel, J.G., Parren, P.W., Bleeker, W.K. Epidermal growth factor receptor (EGFR)
antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting
tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol.
2011;187:3383-90.
• de Weers, M., Tai, Y.T., van der Veer, M.S., Bakker, J.M., Vink, T., Jacobs, D.C., Oomen, L.A.,
Peipp, M., Valerius, T., Slootstra, J.W., Mutis, T., Bleeker, W.K., Anderson, K.C., Lokhorst, H.M.,
van de Winkel, J.G., Parren, P.W. Daratumumab, a novel therapeutic human CD38 monoclonal
antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol.
2011;186:1840-8.
• van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W.K., Martínez-Martínez, P.,
Vermeulen, E., den Bleker, T.H., Wiegman, L., Vink, T., Aarden, L.A., De Baets, M.H., van de
Winkel, J.G., Aalberse, R.C., Parren, P.W.. Anti-inflammatory activity of human IgG4 antibodies
by dynamic Fab arm exchange. Science. 2007;317:1554-7.
 

Relevant patents:

• 7,282,568. Human monoclonal antibodies against interleukin 8 (IL8). Inventors: Teeling,
J., P. Parren, O. Baadsgaard., D. Hudson, J. Peterson. Issued: Oct. 16, 2007.
• 7,438,907. Human monoclonal antibodies against CD25. Inventors: Schuurman, J.,
C.E.G. Havenith, P. Parren, J.G.J. van de Winkel, D.L. Williams, J. Petersen, O. Baadsgaard.
Issued: Oct. 21, 2008.
• 7,622,559. Human monoclonal antibodies against interleukin 8 (IL8). Inventors: Teeling,
J., P. Parren, O. Baadsgaard., D. Hudson, J. Peterson. Issued: Nov. 24, 2009.
• 7,829,673. Antibodies against CD38 for treatment of multiple myeloma. Inventors: De
Weers, M., Y. Graus, J. Oprins, P. Parren, J. van de Winkel, M. van Vugt. Issued: Nov. 9,
2010.
• 7,850,962. Human monoclonal antibodies against CD20. Inventors: Teeling, J., M. Glennie,
P. Parren, A.F. Gerritsen, S. Ruuls, Y. Graus, J. van de Winkel. Issued: Dec. 14, 2010.
• 8,105,588. Human monoclonal antibodies against interleukin 8 (IL8). Inventors: Teeling,
J., P. Parren, O. Baadsgaard., D. Hudson, J. Peterson. Issued: Jan. 31, 2012.
• 8,182,812. Human monoclonal antibodies against CD25. Inventors: Schuurman, J.,
C.E.G. Havenith, P. Parren, J.G.J. van de Winkel, D.L. Williams, J. Petersen, O. Baadsgaard.
Issued: May 22, 2012.
• 8,529,902. Human monoclonal antibodies against CD20. Inventors: Teeling, J., S. Ruuls,
M. Glennie, J. van de Winkel, P. Parren, J. Petersen, O. Baadsgaard, H. Huang. Issued: Sep.
10, 2013.
• EP 1 951 303 B1. Therapy with anti-CD4 antibodies and radiation. Inventors: Parren,
P., O. Baadsgaard, D. Alexander. Issued: Feb. 2, 2011.
• EP 1 590 364 B1. Human monoclonal antibodies against interleukin 8 (IL8). Inventors:
Teeling, J., P. Parren, O. Baadsgaard., D. Hudson, J. Peterson. Issued: Oct. 5, 2011.
• EP 1 572 746 B1. Human monoclonal antibodies to epidermal growth factor receptor
(EGFR)
. Inventors: Van de Winkel, J.G.J., M.A. van Dijk, E. Halk, A.F. Gerritsen, J. Petersen,
O. Baadsgaard, W.K. Bleeker, P. Parren. Issued Nov. 2, 2011.
• EP 1 558 648 B1. Human monoclonal antibodies against CD20. Inventors: Teeling, J.,
S. Ruuls, M. Glennie, J. van de Winkel, P. Parren, J. Petersen, O. Baadsgaard, H. Huang.
Issued Jan. 11, 2012.
• EP 1 578 397 B1. Human monoclonal antibodies against CD25. Inventors: Schuurman,
J., C.E.G. Havenith, P. Parren, J.G.J. van de Winkel, D.L. Williams, J. Petersen, O. Baadsgaard.
Issued: Dec. 26, 2012.
• EP 1 740 946 B1. Human monoclonal antibodies against CD20. Inventors: Teeling, J.,
M. Glennie, P. Parren, A. Gerritsen, S. Ruuls, Y. Graus, J. van de Winkel. Issued: Nov. 6,
2013.
• EP 1 898 698 B1. Non-human mammalian arthritis model featuring human antibodies
against citrullinated peptides
. Inventors: Toes, R., T. Huizinga, M. Molenaar, P. Parren, J.
van de Winkel. Issued: May 21, 2014.
• EP 2 330 130 B1. Human monoclonal antibodies against CD20. Inventors: Teeling, J.,
S. Ruuls, M. Glennie, J. van de Winkel, P. Parren, J. Petersen, O. Baadsgaard, H. Huang.
Issued: August 27, 2014.
• EP 1 960 431 B1. Use of effector-function-defective antibodies for treatment of
auto-immune diseases
. Inventors: Losen, M., P. Martinez-Martinez, M.H. De Baets, Y.
Graus, J. Schuurman, P. Parren. Issued: October 1, 2014.